Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC101
- Development stage
- Preclinical
- Lead developer
- Naia
- Modality
- Small Molecules
- Administration
- Retrograde Instillation Via Ureteral Catheter, Antegrade Instillation Via Nephrostomy Tube
01
Overview
NC101 is a repurposed drug under development by Naia Limited for the treatment of metabolic disorders, including type 2 diabetes mellitus and non-alcoholic steatohepatitis. It acts as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon-like peptide-2 receptor (GLP-2R), making it part of the antihyperglycaemic class. As of the latest available information, it is not a new molecular entity and has not received orphan drug status. The highest reported development phase was preclinical in the United States for both type 2 diabetes mellitus and non-alcoholic steatohepatitis[1].
- Other names
- NC 101NC101NC-101
02
Targets
GLP1R (GLP-1R)GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on NC101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC101.